Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12751300 | 0.83 | KDM4E (0.40) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL30468458 | 0.80 | MAPK1 (0.45) | GPR119MEN1KMT2AUCHL1NR1H2 | |
| SCHEMBL30960950 | 0.76 | SETD7 (0.37) | GPR119SETD7NPC1NR1H2 | |
| SCHEMBL16113465 | 0.76 | OGA (0.43) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL16113467 | 0.76 | OGA (0.43) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL23830485 | 0.75 | KDM4E (0.48) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL31587841 | 0.74 | SETD7 (0.65) | MEN1KMT2ASETD7 | |
| SCHEMBL432224 | 0.73 | SETD7 (0.40) | KDM4EGPR119SETD7NR1H2 | |
| SCHEMBL6745485 | 0.73 | SETD7 (0.38) | GPR119SETD7NR1H2 | |
| SCHEMBL24267329 | 0.73 | SETD7 (0.38) | GPR119SETD7NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915283-B2 | e.g. 1-[4-(1-Phenyl-1-(pyrazinyl)-methylene)-piperidin-1-yl]-2-(4-methoxy-7-pyrazinyl-6-azaindol-3-yl)-ethane-1,2-dione; viricides for prophylaxis of lympadenopathy associated virus; synergystic mixtures with immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | IDO1, IDO2, INMT | KDM4E 111/4885PKM 3253/4885GPR119 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.